KAUST signed an MoU with MISA and Novo Nordisk at the Riyadh Global Medical Biotechnology Summit 2023. The agreement aims to address healthcare challenges in Saudi Arabia and develop the biotech and pharma sector through knowledge transfer and research. A key objective is to establish a Novo Nordisk Center of Excellence focused on obesity and metabolic research. Why it matters: The partnership will boost Saudi Arabia's Vision 2030 goals of creating tech-driven industries and improving health outcomes through biotechnology.
The Saudi Ministry of Health and KAUST have signed an agreement to boost collaboration in healthcare innovation and investment. The partnership aims to develop a sustainable ecosystem supporting applied research and advanced technologies in healthcare, aligning with Saudi Vision 2030. The collaboration includes joint initiatives, workshops, training, and data exchange to enhance health innovation. Why it matters: This agreement signifies a strong push towards AI-based healthcare and precision medicine in Saudi Arabia, leveraging academic research for practical applications.
KAUST is collaborating with medical centers and Alfaisal University to integrate smart and digital tools into the Saudi healthcare system. A key objective is to improve understanding of disease mechanisms for better diagnosis, treatment, and prevention, aligning with KSA's Vision 2030. KAUST has partnered with Alfaisal University to establish the Kingdom’s first M.D./Ph.D. program. Why it matters: These partnerships aim to transition Saudi Arabia's healthcare system towards precision and personalized medicine by training practitioners in AI and smart technologies.
KAUST and the King Salman Center for Disability Research (KSCDR) have signed an MoU to collaborate on the diagnosis, management, and treatment of disabilities affecting Saudi citizens and residents. The partnership will focus on neurodevelopmental conditions, learning disabilities, visual impairments, speech disorders, and mobility impairments. KAUST's Center of Excellence for Smart Health, launched on July 1, will be a key component, leveraging its supercomputing resources and genome sequencing capabilities. Why it matters: This partnership aims to address the increasing prevalence of chronic diseases and disabilities in Saudi Arabia, aligning with national research priorities and improving the quality of life for people with disabilities.
KAUST and Janssen Pharmaceutical (Johnson & Johnson) are collaborating to research and innovate in neglected tropical diseases, focusing on dengue fever. They signed an MoU to establish a dengue fever research program and an infectious disease R&D center at KAUST's National BioPark. The partnership marks Johnson & Johnson's first university collaboration in Saudi Arabia. Why it matters: This collaboration signifies a major step in localizing disease research within Saudi Arabia and leveraging KAUST's AI, genomics, and data simulation expertise to address global health challenges.